Recordati Industria Chimica e Farmaceutica S.p.A (RICFY) Fair Value & Analysis
Healthcare · US · Market cap $11.8B
Recordati Industria Chimica e Farmaceutica S.p.A
RICFY · US
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from $12.47 to $12.38 (−0.7%) since Jun 23, 2026. Share price −12.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $11.79 – $17.87 · fair‑value band $9.29 – $15.48 · the $14.52 price screens above the $12.38 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Recordati Industria Chimica e Farmaceutica S.p.A (RICFY) currently trades at $14.52, while our model-based Fair Value estimate is $12.38 — implying the stock looks roughly 14.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Recordati Industria Chimica e Farmaceutica S.p.A generated revenue of $2.7B at a net margin of 17.8%. Revenue grew 4.9% year over year. It earns a return on equity of 23.4%. Net debt stands at $90.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing's syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasi…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Recordati Industria Chimica e Farmaceutica S.p.A reported revenue of $2.6B in FY2025 versus $1.6B in FY2021, a compound +13.5%/yr. Reported net income was $444M in FY2025, compounding +3.5%/yr from FY2021.
Open the full interactive analysis →
Recent news
- RECORDATI CELEBRATES ITS FIRST 100 YEARS AT TRIENNALE MILANO WITH AN EXHIBITION REVEALING OBJECTS AND IMAGES FROM ITS HISTORICAL ARCHIVE FOR
- 3 European Stocks That May Be Undervalued In May 2026
- Private Equity Prescribes a Delisting for Recordati
- RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2)
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Recordati Industria Chimica e Farmaceutica S.p.A (RICFY) undervalued?
What is the fair value of RICFY?
What is the quality score of RICFY?
What is the revenue of Recordati Industria Chimica e Farmaceutica S.p.A (RICFY)?
What is the net profit margin of RICFY?
Does Recordati Industria Chimica e Farmaceutica S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.